Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCT06587061
HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
- NCT06587061 ↗
- Recruiting
- Ruijin Hospital
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- An Exploratory Clinical Study of HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Pancreatic Cancer
- Interventions
- HRS-4642+AG
- Arms
- HRS-4642, Gemcitabine and Albumin-bound Paclitaxel · Experimental
- Enrollment
- 30 (estimated)
- Primary outcomes
- Adverse events (AEs)
- Objective Response Rate (ORR)
- Sponsor
- Ruijin Hospital with Jiangsu HengRui Medicine Co., Ltd.
- Start
- Dec 3, 2024
- Primary completion
- Jun 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06587061 · updated May 27, 2026